Cagrilintide
Clinical data | |
---|---|
Other names | GLXC-26801 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide.[1][2][3][4][5][6]
References
[edit]- ^ Larsen, Anna T.; Sonne, Nina; Mohamed, Khaled Elhady; Bredtoft, Emma-Marie; Andersen, Frederik; Karsdal, Morten A.; Henriksen, Kim (1 June 2022). "823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats". Diabetes. 71 (Supplement_1). doi:10.2337/db22-823-P. S2CID 249259033.
- ^ Lau, David C W; Erichsen, Lars; Francisco, Ann Marie; Satylganova, Altynai; le Roux, Carel W; McGowan, Barbara; Pedersen, Sue D; Pietiläinen, Kirsi H; Rubino, Domenica; Batterham, Rachel L (December 2021). "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial". The Lancet. 398 (10317): 2160–2172. doi:10.1016/S0140-6736(21)01751-7. PMID 34798060. S2CID 244169045.
- ^ Kruse, Thomas; Hansen, Jakob Lerche; Dahl, Kirsten; Schäffer, Lauge; Sensfuss, Ulrich; Poulsen, Christian; Schlein, Morten; Hansen, Ann Maria Kruse; Jeppesen, Claus Bekker; Dornonville de la Cour, Charlotta; Clausen, Trine Ryberg; Johansson, Eva; Fulle, Simone; Skyggebjerg, Rikke Bjerring; Raun, Kirsten (12 August 2021). "Development of Cagrilintide, a Long-Acting Amylin Analogue". Journal of Medicinal Chemistry. 64 (15): 11183–11194. doi:10.1021/acs.jmedchem.1c00565. ISSN 0022-2623. PMID 34288673. S2CID 236175929.
- ^ Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D; Davies, Melanie (August 2023). "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial". The Lancet. 402 (10403): 720–730. doi:10.1016/S0140-6736(23)01163-7. PMID 37364590. S2CID 259237278.
- ^ D’Ascanio, Antonella M.; Mullally, Jamie A.; Frishman, William H. (8 March 2023). "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity". Cardiology in Review. Publish Ahead of Print. doi:10.1097/CRD.0000000000000513. PMID 36883831. S2CID 257404657.
- ^ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; Henriksen, K. (1 December 2022). "Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy. 156: 113842. doi:10.1016/j.biopha.2022.113842. ISSN 0753-3322. PMID 36242844. S2CID 252881350.